Trying to understand better current status of Dried matrix methods (DMM) and Mircorsampling [updated question to include Microsampling (blood/plasma) and webinar details] - Aug 18 2022 - Thu, Sep 15 2022, 14:00 - 16:00 - UK Webinar: Microsampling in toxicology – Maximising the scientific, business and 3Rs advantages https://www.nc3rs.org.uk/events/webinar-microsampling-toxicology-maximising-scientific-business-and-3rs-advantages

[updated with some resources/publications] - May 2 2022

Except from M10 BIOANALYTICAL METHOD VALIDATION (DRAFT Guidance)

When DMM is used for clinical or nonclinical studies in addition to typical liquid approaches (e.g., liquid plasma samples) in the same studies, these two methods should be cross validated as described (Refer to Section 6.2). For nonclinical TK studies, refer to Section 4.1 of ICH S3A Q&A. Feedback from the appropriate regulatory authorities is encouraged in early drug development.

M10 BIOANALYTICAL METHOD VALIDATION (DRAFT Guidance)

https://www.fda.gov/media/128343/download

S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling Questions and Answers Guidance for Industry

https://www.fda.gov/files/drugs/published/S3A-Guidance--Note-for-Guidance-on-Toxicokinetics--The-Assessment-of-Systemic-Exposure-in-Toxicity-Studies--Focus-on-Microsampling.pdf

References published after draft guidance.

Article Opportunities and obstacles for microsampling techniques in ...

Article Application of tail vein serial microsampling for plasma or ...

Article Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Us...

Interesting company/products [no relationship with company or product]

" Neoteryx delivers smarter, simpler remote specimen collection with VAMS technology. " https://www.neoteryx.com/